During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD, chaired a livestreamed RCC session that included lively discussion from Mike Atkins, MD; David McDermott, MD; and Brian Rini, MD.
Together, they weigh the results of the RENOTORCH study findings presented at ESMO and whether those data influenced their opinions on first-line IO treatment for metastatic disease. They also consider the results of CheckMate 214, KEYNOTE-426, CheckMate 9ER, and CLEAR.
View the first kidney cancer session of the day on management of IO-refractory disease.